|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Licensing Strategies: Best Practices in Deal-Making, Valuations and Strategic Management
Business Insights, June 2006, Pages: 116
With falling R&D productivity, continued healthcare cost containment and the threat of generic competition, only those companies who combine internal efforts with effective licensing strategies will remain competitive over the next five-to-ten years.
Pharmaceutical Licensing Strategies: Best practices in deal-making, valuations and strategic management is the only report available that combines up-to-date analysis of recent deal trends and best practices with a detailed guide to the licensing and deal-making process, ensuring that you are able to optimize your strategic licensing activities.
Use this report to ensure that you are up-to-date with the latest licensing trends and can implement strategies that will drive ‘win-win’ licensing deals. Give your licensing strategies the best chance of success and enhance your reputation within the industry to become the partner of choice.
' While an understanding of total deal values are generated by the base case model, negotiations around licensing agreements are informed by looking at how that value is shared between potential partners with respect to risks, returns and responsibilities. The first model outputs outline all potential cash flows for each partner over the lifecycle of the licensing agreement...'
Key findings of the report...
- The larger biotech companies now have the resources and the capabilities to develop lead drugs to later stages of development before seeking a pharmaceutical partner, and are now able to compete with pharmaceutical companies for the best in-licensing deals from emerging biotech.
- While the value of licensing deals has risen markedly in the last 5 years, the volume of deals among the top companies has plateaued. Companies are increasingly seeking out long-term, multi-product, multi-indication collaborations rather than one-off transactional deals.
- Using independent and unbiased model inputs in the licensing valuation process limits areas of subjective disagreement, and allows deal terms to be maximized for both parties.
- A successful deal cannot only be judged by deal terms and revenues gained from the eventual product; the quality of the relationship between licensing partners is also equally important.
'A survey of 142 licensing executives revealed Novartis to be the in-licensing partner of choice in 2006. Other leading in-licensing partners include Pfizer, Johnson & Johnson (J&J) and Roche. Interestingly, Amgen was the fourth ranked in-licensing company, illustrating the biotech company’s affinity with smaller biotech companies as a preferred alternative partner to big pharma...'
Key questions answered in this report:
- What are the best practice strategies in developing an effective win-win licensing deal?
- How does the licensing process differ for in-licensing and out-licensing companies?
- How do outside agencies, consultancies and investors help to support the licensing process?
- What can be done to optimize licensing deal values through collaborative evaluations?
- What lessons can be drawn from the key successful deals and deal-makers of the past 10 years?
- How is the value, volume and competition for licensing deals forecast to change over the coming year?
- Why are companies now forming more relationship-based licenses than ever before?
'the sharing of (valuation) information with a potential partner is far greater for pharmaceutical companies than it is for biotech companies. This means that a greater proportion of biotech companies are withholding valuation data from their partners than is the case for pharmaceutical companies...'
Top five reasons to order your copy today:
1. Understand how the dynamics of licensing deals have changed in the last 5 years, including the increasing complexity of multiple development compound deals and the shifting balance of power between the licensee and licensor.
2. Gain access to a survey of over 140 licensing experts ensuring you implement optimal licensing processes and commit adequate resources to support deal-making.
3. Profile the leading deals and deal-makers over the past 5 years, identify the key factors of success and apply the report’s actionable recommendations.
4. Implement effective alliance management processes to ensure the success of your current licensing deals and become the partner of choice for the future.
5. Apply the independent licensing valuation model presented in this report in order to begin more collaborative licensing negotiations and maximize the value of your deal for both parties.
'Looking at biotech R&D licensing deals specifically, there appears to have been a significant trend towards later stage deals between 2001 and 2005. For biotech R&D licensing deals, the proportion of agreements signed in phase II or later has grown from less than 20% in 2001 to almost 30% in 2005. Licensing agreements in later stages, particularly in phase II, appear to be driving growth in licensing activity over the past five years... '
Customers who bought this item also bought
Licensing Strategies - Examining Today’s Pharmaceutical Licensing Trends
The Survey of Library Database Licensing Practices
Optimizing Licensing Strategies for the 21st Century: Creating Win-Win Pharmaceutical and Biotech Licensing Deals
Guide to Valuation of Pharmaceutical Licensing Deals
Evolving Trends in Biopharmaceutical Licensing: Deal Assessments, Drivers and Resistors
Bio-Device Licensing: Strategies for Success
Licensing Strategies: Trends In The Top 20 Pharmaceutical Companies Activity
Licensing Strategies: Benchmarking Analysis of the Top 20 Pharmaceutical Companies
The Licensing Agreement in Pharmaceutical Business Development: 3rd edition
Evolving Trends in Licensing: Strategies for Building and Retaining Value in Biotechnology Alliances
Effective Licensing & Commercialisation of Drug Delivery Systems 2006
The Pharmaceutical Licensing Outlook: A Strategic Guide To Effective Deal-Making And Profitable Partnerships
|
|
|
|
